Heart disease: Experimental cancer drug may slow inflammation from atherosclerosis; High-profile coverage of the off-label use of Ozempic, a GLP-1 agonist, for weight loss, has meant that the type 2 diabetes drug has received a lot of bad press. As more s

  • Chiara Giannarelli

Press/Media

Period8 Jun 2023

Media coverage

1

Media coverage

  • TitleHeart disease: Experimental cancer drug may slow inflammation from atherosclerosis; High-profile coverage of the off-label use of Ozempic, a GLP-1 agonist, for weight loss, has meant that the type 2 diabetes drug has received a lot of bad press. As more s
    Media name/outletMedical News Today
    Country/TerritoryUnited Kingdom
    Date8/06/23
    URLct.moreover.com/?a=51006636666&p=1gw&v=1&x=GWUgIrF7pO52ziPkqp835g
    PersonsChiara Giannarelli